CRISM THERAPEUTICS CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.325 GBX | +0.91% |
|
-12.37% | -42.19% |
| May. 31 | Crism has first day of trade on AIM after name change, buy | AN |
| May. 29 | Amur Minerals confirms Extruded buy, name change and board shake-up | AN |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 35.42 | 22.25 | 30.19 | 31.83 | 16.85 | 1.564 |
| Enterprise Value (EV) 1 | 35.83 | 21.85 | 27.4 | 25.15 | 13.36 | -2.82 |
| P/E ratio | -10.2 x | -8.86 x | -8.78 x | -26.4 x | -5.59 x | -0.16 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -17 x | -11 x | -8.88 x | -14.1 x | -6.86 x | - |
| EV / FCF | -12.6 x | -9.62 x | -14.1 x | -0.99 x | -5.09 x | -0.12 x |
| FCF Yield | -7.91% | -10.4% | -7.09% | -101% | -19.6% | -826% |
| Price to Book | 1.5 x | 0.77 x | 0.96 x | 1.06 x | 0.61 x | 0.38 x |
| Nbr of stocks (in thousands) | 4,287 | 5,284 | 8,624 | 8,624 | 8,705 | 8,705 |
| Reference price 2 | 8.262 | 4.211 | 3.501 | 3.691 | 1.935 | 0.1796 |
| Announcement Date | 6/25/19 | 6/26/20 | 6/30/21 | 6/30/22 | 6/30/23 | 5/10/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -2.113 | -1.979 | -3.084 | -1.783 | -1.947 | - |
| EBIT 1 | -2.118 | -1.984 | -3.089 | -1.788 | -2.224 | -2.084 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -3.308 | -2.329 | -2.668 | -1.79 | -2.605 | -2.391 |
| Net income 1 | -3.308 | -2.329 | -2.668 | -1.206 | -3.013 | -9.647 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.8061 | -0.4752 | -0.3985 | -0.1398 | -0.3464 | -1.108 |
| Free Cash Flow 1 | -2.834 | -2.272 | -1.943 | -25.42 | -2.625 | 23.29 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 6/25/19 | 6/26/20 | 6/30/21 | 6/30/22 | 6/30/23 | 5/10/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.41 | - | - | - | - | - |
| Net Cash position 1 | - | 0.4 | 2.79 | 6.68 | 3.48 | 4.38 |
| Leverage (Debt/EBITDA) | -0.1921 x | - | - | - | - | - |
| Free Cash Flow 1 | -2.83 | -2.27 | -1.94 | -25.4 | -2.63 | 23.3 |
| ROE (net income / shareholders' equity) | -12.7% | -9.09% | -9.12% | -5.82% | -8.99% | -15% |
| ROA (Net income/ Total Assets) | -4.75% | -4.5% | -6.36% | -3.51% | -4.63% | -7.77% |
| Assets 1 | 69.61 | 51.78 | 41.92 | 34.34 | 65.01 | 124.2 |
| Book Value Per Share 2 | 5.510 | 5.500 | 3.640 | 3.490 | 3.200 | 0.4700 |
| Cash Flow per Share 2 | 0.2900 | 0.0800 | 0.3200 | 0.7700 | 0.4000 | 0.5000 |
| Capex 1 | 2.05 | 0.5 | 0.56 | 0.43 | 0.33 | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 6/25/19 | 6/26/20 | 6/30/21 | 6/30/22 | 6/30/23 | 5/10/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -42.19% | 914K | |
| -11.66% | 149B | |
| -8.77% | 116B | |
| -0.41% | 72.64B | |
| -7.72% | 43.88B | |
| +1.03% | 40.47B | |
| +20.04% | 36.77B | |
| +110.69% | 34.81B | |
| +20.84% | 25.54B | |
| +72.29% | 20.48B |
- Stock Market
- Equities
- CRTX Stock
- Financials CRISM Therapeutics Corporation
